Adecto blames ‘risk-adverse funding environment’ for closing
Adecto blames ‘risk-adverse funding environment’ for closing
Preclinical-stage oncology biotechnology company developing antibody therapeutics and diagnostics targeting the ADAM8 cell-surface protein, a driver of multiple aggressive cancers.
Adecto blames ‘risk-adverse funding environment’ for closing
Chief Executive Officer & Co-Founder
Co-Founder & President